Nephrogenic systemic fibrosis (NSF): a late adverse reaction to some of the gadolinium based contrast agents

Abstract

Nephrogenic systemic fibrosis (NSF): a late adverse reaction to some of the gadolinium based contrast agents - Cancer Imaging Nephrogenic systemic fibrosis (NSF): a late adverse reaction to some of the gadolinium based contrast agents - Until recently it was believed that extracellular gadolinium based contrast agents were safe for both the kidneys and all other organs within the dose range up to 0.3 mmol/kg body weight. However, in 2006, it was demonstrated that some gadolinium based contrast agents may trigger the development of nephrogenic systemic fibrosis, a generalised fibrotic disorder, in renal failure patients. Accordingly, the use of gadodiamide and gadopentate dimeglumine for renal failure patients was banned in Europe in spring 2007.